Advertisement

Rheumatology International

, Volume 35, Issue 2, pp 295–302 | Cite as

Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria

  • Pascal ZuffereyEmail author
  • Jacqueline Ghosn
  • Fabio Becce
  • Adrian Ciurea
  • Bérengère Aubry-Rozier
  • Axel Finckh
  • Alexander K. So
Original Article

Abstract

To compare the impact of meeting specific classification criteria [modified New York (mNY), European Spondyloarthropathy Study Group (ESSG), and Assessment of SpondyloArthritis international Society (ASAS) criteria] on anti-tumor necrosis factor (anti-TNF) drug retention, and to determine predictive factors of better drug survival. All patients fulfilling the ESSG criteria for axial spondyloarthritis (SpA) with available data on the axial ASAS and mNY criteria, and who had received at least one anti-TNF treatment were retrospectively retrieved in a single academic institution in Switzerland. Drug retention was computed using survival analysis (Kaplan–Meier), adjusted for potential confounders. Of the 137 patients classified as having axial SpA using the ESSG criteria, 112 also met the ASAS axial SpA criteria, and 77 fulfilled the mNY criteria. Drug retention rates at 12 and 24 months for the first biologic therapy were not significantly different between the diagnostic groups. Only the small ASAS non-classified axial SpA group (25 patients) showed a nonsignificant trend toward shorter drug survival. Elevated CRP level, but not the presence of bone marrow edema on magnetic resonance imaging (MRI) scans, was associated with significantly better drug retention (OR 7.9, ICR 4–14). In this cohort, anti-TNF drug survival was independent of the classification criteria. Elevated CRP level, but not positive MRI, was associated with better drug retention.

Keywords

Axial spondyloarthritis Classification criteria Anti-tumor necrosis factor Drug survival 

Supplementary material

296_2014_3094_MOESM1_ESM.pptx (213 kb)
Supplementary material 1 (PPTX 212 kb)

References

  1. 1.
    Sieper J (2009) Developments in the scientific and clinical understanding of the spondyloarthritides. Arthritis Res Ther 11(1):208. doi: 10.1186/ar2562 PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sorensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777–783. doi: 10.1136/ard.2009.108233 PubMedCrossRefGoogle Scholar
  3. 3.
    Sieper J (2011) Spondyloarthropathies in 2010: new insights into therapy-TNF blockade and beyond. Nat Rev Rheumatol 7(2):78–80. doi: 10.1038/nrrheum.2010.224 PubMedCrossRefGoogle Scholar
  4. 4.
    van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, Rudwaleit M, Braun J, Assessment of SpondyloArthritis international S (2011) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70(6):905–908. doi: 10.1136/ard.2011.151563 PubMedCrossRefGoogle Scholar
  5. 5.
    Goh L, Samanta A (2009) A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int 29(10):1123–1135. doi: 10.1007/s00296-009-0973-9 PubMedCrossRefGoogle Scholar
  6. 6.
    Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, van der Heijde D (2011) ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 70(2):249–251. doi: 10.1136/ard.2010.133488 PubMedCrossRefGoogle Scholar
  7. 7.
    Sieper J, van der Heijde D, Dougados M, Brown LS, Lavie F, Pangan AL (2012) Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 71(5):700–706. doi: 10.1136/annrheumdis-2011-200358 PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Gerard S, le Goff B, Maugars Y, Berthelot JM (2008) Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A “real life” retrospective study on 175 patients. Joint Bone Spine 75(6):680–687. doi: 10.1016/j.jbspin.2008.03.006 PubMedCrossRefGoogle Scholar
  9. 9.
    Ciurea A, Scherer A, Exer P, Bernhard J, Dudler J, Beyeler B, Kissling R, Stekhoven D, Rufibach K, Tamborrini G, Weiss B, Mueller R, Nissen MJ, Michel BA, van der Heijde D, Dougados M, Boonen A, Weber U, Rheumatologists of the Swiss Clinical Quality Management Program for Axial S (2013) Tumor necrosis factor-alpha inhibition in radiographic and non-radiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum. doi: 10.1002/art.38140 PubMedGoogle Scholar
  10. 10.
    Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, Swiss Clinical Quality Management P (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61(5):560–568. doi: 10.1002/art.24463 PubMedCrossRefGoogle Scholar
  11. 11.
    Glintborg B, Ostergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen PM, Hetland ML (2013) Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 72(7):1149–1155. doi: 10.1136/annrheumdis-2012-201933 PubMedCrossRefGoogle Scholar
  12. 12.
    Sieper J, van der Heijde D, Landewe R, Brandt J, Burgos-Vagas R, Collantes-Estevez E, Dijkmans B, Dougados M, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Rudwaleit M (2009) New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 68(6):784–788. doi: 10.1136/ard.2008.101501 PubMedCrossRefGoogle Scholar
  13. 13.
    Calin A (1987) Diagnostic criteria (new and old) for the spondylarthropathies. Clin Exp Rheumatol 5(2):101–102PubMedGoogle Scholar
  14. 14.
    Rudwaleit M, Jurik AG, Hermann KG, Landewe R, van der Heijde D, Baraliakos X, Marzo-Ortega H, Ostergaard M, Braun J, Sieper J (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68(10):1520–1527. doi: 10.1136/ard.2009.110767 PubMedCrossRefGoogle Scholar
  15. 15.
    Luc M, Gossec L, Ruyssen-Witrand A, Salliot C, Duclos M, Guignard S, Dougados M (2007) C-reactive protein predicts tumor necrosis factor-alpha blocker retention rate in axial ankylosing spondylitis. J Rheumatol 34(10):2078–2081PubMedGoogle Scholar
  16. 16.
    Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J (2008) MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67(9):1276–1281. doi: 10.1136/ard.2007.073098 PubMedCrossRefGoogle Scholar
  17. 17.
    Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J, Rudwaleit M (2012) Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 64(5):1388–1398. doi: 10.1002/art.33465 PubMedCrossRefGoogle Scholar
  18. 18.
    Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P (2010) Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res 62(10):1362–1369. doi: 10.1002/acr.20258 CrossRefGoogle Scholar
  19. 19.
    Bereau M, Prati C, Wendling D (2011) Sacroiliac edema by MRI does not always indicate spondylarthritis. Joint Bone Spine 78(6):646. doi: 10.1016/j.jbspin.2011.05.011 PubMedCrossRefGoogle Scholar
  20. 20.
    Poddubnyy D, Brandt H, Vahldiek J, Spiller I, Song IH, Rudwaleit M, Sieper J (2012) The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic. Ann Rheum Dis 71(12):1998–2001. doi: 10.1136/annrheumdis-2012-201945 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Pascal Zufferey
    • 1
    Email author
  • Jacqueline Ghosn
    • 1
  • Fabio Becce
    • 2
  • Adrian Ciurea
    • 3
  • Bérengère Aubry-Rozier
    • 1
  • Axel Finckh
    • 4
  • Alexander K. So
    • 1
  1. 1.Department of RheumatologyLausanne University HospitalLausanneSwitzerland
  2. 2.Department of Diagnostic and Interventional RadiologyLausanne University HospitalLausanneSwitzerland
  3. 3.Department of RheumatologyUniversity Hospital ZurichZurichSwitzerland
  4. 4.Department of RheumatologyUniversity Hospital GenevaGenevaSwitzerland

Personalised recommendations